Jazz Pharmaceuticals Reports 2026 Annual Meeting Vote Results

What Happened

• Jazz Pharmaceuticals plc (JAZZ) filed an 8-K reporting the results of its Annual General Meeting held July 23, 2026 at its Dublin headquarters. Holders of 57,836,785 of the 62,817,628 ordinary shares entitled to vote were present in person or by proxy.
• Three director nominees were elected to serve until the 2029 annual meeting: Bruce C. Cozadd, Heather Ann McSharry, and Rick E. Winningham. Other proposals — including ratification of auditors, advisory approval of executive compensation, and authorities to allot and issue ordinary shares under Irish law — were approved as detailed below. Proposal 6 (motion to adjourn if needed) was not put to a vote because no adjournment motion was made.

Key Details

• Director election votes:
  • Bruce C. Cozadd — For: 51,881,319; Against: 2,101,752; Abstain: 16,716; Broker non-votes: 3,836,998.
  • Heather Ann McSharry — For: 46,088,894; Against: 7,806,697; Abstain: 104,196; Broker non-votes: 3,836,998.
  • Rick E. Winningham — For: 51,869,443; Against: 2,025,769; Abstain: 104,575; Broker non-votes: 3,836,998.
• Auditor ratification (non-binding advisory) and remuneration authorization: KPMG, Dublin was approved — For: 56,675,189; Against: 1,142,004; Abstain: 19,592.
• Say-on-pay (advisory approval of named executive officer compensation) was approved — For: 50,608,405; Against: 3,345,782; Abstain: 45,600; Broker non-votes: 3,836,998.
• Share issuance authorities under Irish law approved:
  • General authority to allot and issue ordinary shares — For: 56,427,298; Against: 1,274,823; Abstain: 134,664.
  • Authority to allot and issue ordinary shares for cash without statutory pre-emption — For: 55,827,950; Against: 1,873,047; Abstain: 135,788.

Why It Matters

• The board slate was confirmed, keeping the current governance team in place through 2029, which provides continuity in leadership and strategy execution.
• Ratification of KPMG as auditors and the authorized remuneration process ensures the company’s external audit arrangement is supported by shareholders.
• Approval of share allotment authorities (including the waiver of pre-emption rights for cash issuances) gives the board legal flexibility to issue shares for financing or strategic purposes under Irish law — a change investors should note because such authority can enable capital raises that may dilute existing shareholders if exercised.
• The advisory approval of executive compensation passed (non-binding), signaling shareholder support for the company’s pay practices but without direct legal effect.

Filed and signed by Neena Patil, Executive Vice President and Chief Legal Officer, on July 24, 2026.